YIH
NMRA icon

Y-Intercept (HK)’s Neumora Therapeutics NMRA Stock Holding History

Y-Intercept (HK)’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-57,072
Closed -$41.9K – 1881
2025
Q2 		$41.9K Buy
+57,072
New +$43.2K ﹤0.01% 1567

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Y-Intercept (HK)'s NMRA Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Neumora Therapeutics (NMRA) in Q3 2025, closing a stake of 57,072 shares — an estimated $41.9K sold.

Y-Intercept (HK) first reported a position in NMRA in Q2 2025 and held it in 1 quarter. The position peaked at $41.9K in Q2 2025. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Neumora Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 57,072 Neumora Therapeutics shares in Q3 2025, an estimated $41.9K.
  • Y-Intercept (HK) first reported a position in Neumora Therapeutics in Q2 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Neumora Therapeutics position peaked at $41.9K in Q2 2025.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.